8-K ·Filed May 7, 2026

KOD

Kodiak Sciences Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4mo ago SEC0001193125-26-211811
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Traders should focus on upcoming catalysts: DAYBREAK (Sep 2026) and PEAK (Q4 2026) Phase 3 data. Cash runway into 2027 provides a buffer. No guidance change; stock likely to trade on pipeline news rather than financials.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
KOD ▲ +4.58% at T+60d
NEUTRAL call ✓ call won +4.58% · α vs SPY -0.26% · entry $41.01 → $42.89
Entry anchored
May 7, 03:59 PM ET
via exchange tick
T+1d
-2.83%
call -2.83% · α -3.06%
$39.85
settled 5mo ago
T+5d
-5.63%
call -5.63% · α -7.10%
$38.70
settled 5mo ago
T+20d
-24.29%
call -24.29% · α -24.31%
$31.05
settled 4mo ago
T+60d
+4.58%
call +4.58% · α -0.26%
$42.89
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs $57.5M ($1.09/share) in Q1 2025, essentially in line with consensus of $0.93. The pre-revenue biotech highlighted positive GLOW2 data and expects DAYBREAK (Sep 2026) and PEAK (Q4 2026) Phase 3 readouts. Cash of $169.5M is expected to fund operations into 2027.

Key Financial Metrics

EPS
$-0.94
est $-0.93 · -1.1%
Rating
in line

Key Facts

  • Net loss $58.2M, or $0.94 per share, vs $57.5M ($1.09) in Q1 2025
  • Cash and cash equivalents $169.5M, down from $209.9M at Dec 31, 2025
  • R&D expenses $48.5M vs $43.6M YoY, driven by increased clinical activities
  • Zenkuda BLA submission planned; DAYBREAK topline data expected Sep 2026
  • KSI-101 Phase 3 PEAK topline expected Q4 2026, PINNACLE Q2 2027
  • No revenue; company is pre-commercial

Financial Impact

Net loss per share $0.94 vs consensus $0.93, essentially in line. Cash burn ~$40M in the quarter.

net losscash positionR&D spend

Risk Factors

  • Potential delays or failures in Phase 3 trials (DAYBREAK, PEAK, PINNACLE)
  • Cash burn rate may require additional financing before readouts
  • BLA submission and approval risks for Zenkuda

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-211811
Document: kod-20260507.htm0001193125-26-211811
Document: 0001193125-26-211811-index-headers.html0001193125-26-211811
Document: 0001193125-26-211811-index.html0001193125-26-211811
Document: 0001193125-26-211811.txt0001193125-26-211811
8-K Data (Synthetic)0001193125-26-211811
5 reports for KOD
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for KOD — sortable, filterable
TypeNow
Aug 13, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$41.35 $33.14▼ −19.85%▼ −17.86%$94.45 (+128.42%)
Aug 13, 2026
7w ago
Press Release
NEUTRAL ★ 6/10
$41.35 $33.14▼ −19.85%▼ −17.86%$94.45 (+128.42%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 4/10
$33.97 $40.08▲ +17.99%▲ +16.10%$94.45 (+178.04%)
May 7, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$41.01 $31.05▼ −24.29%▼ −24.31%$94.45 (+130.31%)
Mar 31, 2026
26w ago
8-K
BULLISH ★ 8/10
$42.81 $43.67▲ +2.01%▼ −7.71%$94.45 (+120.63%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (64h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access